Exploration of Multitarget Anti-Breast Cancer Potential of Selected Flavonoids Through Network Pharmacology and Molecular Docking

Nisriinaa Ayu Dewanto, Btari Kalisha Nyratri, Reneta Aisyah Maulina Junus, Dzava Prawinsyah Fairus Ismail, Yuni Elsa Hadisaputri

Abstrak


Breast cancer remains a leading cause of mortality among women worldwide, including in Indonesia. Although current therapies such as chemotherapy, radiotherapy, and hormone therapy have improved patient outcomes, their effectiveness is frequently limited by systemic toxicity and multidrug resistance. In this study, the therapeutic potential of six natural flavonoid compounds was evaluated using a computational biology approach. Network pharmacology analysis identified estrogen receptor (ER-ɑ) (PDB ID: 3ERT), anti-apoptotic protein (BCL-2) (PDB ID: 6GL8), and DNA repair enzyme (PARP1) (PDB ID: 4R6E) as key molecular targets involved in breast cancer progression. The compounds were assessed through molecular docking, Lipinski’s Rule of Five, and absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) predictions to identify promising candidates with favorable pharmacokinetic and safety profiles. Among the evaluated compounds, rutin and kaempferol exhibited the most favorable overall characteristics based on binding affinity and predicted toxicity. These findings provide preliminary computational evidence supporting the potential of these flavonoids as lead candidates for further development. Nevertheless, experimental validation through molecular dynamics and biological studies is required to confirm their therapeutic relevance.


Kata Kunci


Breast cancer therapy; Cancer apoptotic pathway; Hormone receptor antagonists; In silico analysis; Natural compound screening

Teks Lengkap:

PDF

Referensi


Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263.

Obeagu EI, Obeagu GU. Breast cancer: A review of risk factors and diagnosis. Medicine (United States). 2024;103(3):E36905.

Ryspayeva D, Seyhan AA, MacDonald WJ, Purcell C, Roady TJ, Ghandali M et al. Signaling pathway dysregulation in breast cancer. Oncotarget. 2025;16:168–201.

Saha S, Mahapatra S, Khanra S, Mishra B, Swain B, Malhotra D et al. Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectives. Cancer Drug Resistance. 2025;8:36.

Langeh U, Kumar V, Ahuja P, Singh C, Singh A. An update on breast cancer chemotherapy-associated toxicity and their management approaches. Health Sciences Review. 2023;9: 100119.

Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA - Journal of the American Medical Association. 2019;321(3):288–300.

Montazeri A, Vahdaninia M, Harirchi I, Ebrahimi M, Khaleghi F, Jarvandi S. Quality of life in patients with breast cancer before and after diagnosis: An eighteen months follow-up study. BMC Cancer. 2008;8:330.

Kopustinskiene DM, Jakstas V, Savickas A, Bernatoniene J. Flavonoids as anticancer agents. Nutrients. 2020;12(2):457.

Rodríguez-García C, Sánchez-Quesada C, Gaforio JJ, Gaforio JJ. Dietary flavonoids as cancer chemopreventive agents: An updated review of human studies. Antioxidants. 2019;8(5):137.

Cheon M, Chung M, Park Y. Association between dietary intake of flavonoids and cancer recurrence among breast cancer survivors. Nutrients. 2021;13(9):3049.

Yuan Y, Yu L, Bi C, Huang L, Su B, Nie J et al. A new paradigm for drug discovery in the treatment of complex diseases: drug discovery and optimization. Chin Med. 2025;20:40.

Gupta Y, Savytskyi O V., Coban M, Venugopal A, Pleqi V, Weber CA et al. Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics. Mol Aspects Med. 2023;91:101151.

Chandran U, Mehendale N, Patil S, Chaguturu R, Patwardhan B. Network Pharmacology. In: Innovative Approaches in Drug Discovery: Ethnopharmacology, Systems Biology and Holistic Targeting. Elsevier Inc. 2017:127–164.

Li L, Yang L, Yang L, He C, He Y, Chen L et al. Network pharmacology: a bright guiding light on the way to explore the personalized precise medication of traditional Chinese medicine. Chin Med. 2023;18(1):146.

Li L, Kar S. Leveraging network pharmacology for drug discovery: Integrative approaches and emerging insights. Med Drug Discov. 2025;27:100220.

Agu PC, Afiukwa CA, Orji OU, Ezeh EM, Ofoke IH, Ogbu CO et al. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci Rep. 2023;13.

Guan L, Yang H, Cai Y, Sun L, Di P, Li W et al. ADMET-score-a comprehensive scoring function for evaluation of chemical drug-likeness. Medchemcomm. 2019;10(1): 148–157.

Amorim AMB, Piochi LF, Gaspar AT, Preto AJ, Rosário-Ferreira N, Moreira IS. Advancing Drug Safety in Drug Development: Bridging Computational Predictions for Enhanced Toxicity Prediction. Chem Res Toxicol. 2024; 37(6): 827–849.

Elalouf A, Rosenfeld AY, Maoz H. Targeting serotonin receptors with phytochemicals – an in-silico study. Sci Rep 2024; 14.

Benet LZ, Hosey CM, Ursu O, Oprea TI. BDDCS, the Rule of 5 and drugability. Adv Drug Deliv Rev. 2016; 101:89–98.

Kurnia D, Putri SA, Tumilaar SG, Zainuddin A, Dharsono HDA, Amin MF. In silico Study of Antiviral Activity of Polyphenol Compounds from Ocimum basilicum by Molecular Docking, ADMET, and Drug-Likeness Analysis. Advances and Applications in Bioinformatics and Chemistry. 2023;16:37–47.

Nhlapho S, Nyathi M, Ngwenya B, Dube T, Telukdarie A, Munien I et al. Druggability of Pharmaceutical Compounds Using Lipinski Rules with Machine Learning. Sciences of Pharmacy. 2024;3(4):177–192.

Zhang B, Tang L, Tian F, Ding Q, Hu Z, Wang J-R et al. Rutin Cocrystals with Improved Solubility, Bioavailability, and Bioactivities. Cryst Growth Des. 2024;24(2):5637–5647.

Bharathi D, Bhuvaneshwari V. Synthesis of zinc oxide nanoparticles (ZnO NPs) using pure bioflavonoid rutin and their biomedical applications: antibacterial, antioxidant and cytotoxic activities. Research on Chemical Intermediates. 2019;45:2065–2078.

Kunjiappan S, Panneerselvam T, Govindaraj S, Parasuraman P, Baskararaj S, Sankaranarayanan M et al. Design, In Silico Modelling, and Functionality Theory of Novel Folate Receptor Targeted Rutin Encapsulated Folic Acid Conjugated Keratin Nanoparticles for Effective Cancer Treatment. Anticancer Agents Med Chem. 2020;19(16):1966–1982.

Clusan L, Ferrière F, Flouriot G, Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int J Mol Sci. 2023;24(7):6834.

Miziak P, Baran M, Błaszczak E, Przybyszewska-Podstawka A, Kałafut J, Smok-Kalwat J et al. Estrogen Receptor Signaling in Breast Cancer. Cancers (Basel). 2023;15(19):4689.

Tecalco-Cruz AC, Ramírez-Jarquín JO. Mechanisms that Increase Stability of Estrogen Receptor Alpha in Breast Cancer. Clin Breast Cancer. 2017;17(1):1–10.

Kaloni D, Diepstraten ST, Strasser A, Kelly GL. BCL-2 protein family: attractive targets for cancer therapy. Apoptosis. 2023; 28:20–38.

Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022; 12:985363.

Alemasova EE, Lavrik OI. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins. Nucleic Acids Res. 2019;47(8):3811–3827.

Nambiar DK, Mishra D, Singh RP. Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials. Oncol Res. 2023;31(4):405–421.

Chaudhuri AR, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18(10):610–621.

Zong C, Zhu T, He J, Huang R, Jia R, Shen J. PARP mediated DNA damage response, genomic stability and immune responses. Int J Cancer. 2022;150(11):1745–1759.

Hong T, Chen W, Ren Y-T, Wang Y-H, Lu D-Q, Zhang K-Y et al. Network pharmacology identifies the inhibitory effect of Yiqiyangyinquyu prescription on salivary gland inflammation in Sjögren’s syndrome. Medicine. 2023;102(47):e36144.

Liu Y, Shen G, Xia Z, Wang R, Dai Y. Analysis of potential molecular targets and mechanisms of brominated flame retardants in causing osteoarthritis using network toxicology, machine learning, SHAP analysis, and molecular dynamics simulation. BMC Pharmacol Toxicol. 2025;26(1):150.

Pang X, Fu W, Wang J, Kang D, Xu L, Zhao Y et al. Identification of Estrogen Receptor α Antagonists from Natural Products via In Vitro and In Silico Approaches. Oxid Med Cell Longev 2018; 2018:6040149.

Ren J, Quan X, Liu Y, Li J, Zhang X, Li Z et al. Synthesis and in vitro biological evaluation of 3-ethyl-1,5-naphthyridin-2(1H)-one derivatives as potent PARP-1 selective inhibitors and PARP-1 DNA trappers. Bioorg Med Chem Lett. 2022;78:129046.

Maeda J, Roybal EJ, Brents CA, Uesaka M, Aizawa Y, Kato TA. Natural and glucosyl flavonoids inhibit poly(ADP-ribose) polymerase activity and induce synthetic lethality in BRCA mutant cells. Oncol Rep. 2014;31(2):551–556.

Permana S, Nurzaidah L, Widodo E, Anita KW, Nugraheni RW, Kawamoto Y et al. Anticancer activity of Hedyotis corymbosa nanoliposomes targeting estrogen receptor-alpha in breast cancer cells: In silico and in vitro studies. J Pharm Pharmacogn Res. 2024;12(3):303–322.

Casara P, Davidson J, Claperon A, Le Toumelin-Braizat G, Vogler M, Bruno A et al. S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget. 2018;9(28):20075–20088.

Yi X, Tan C, Zuo J, Xian S, Luo C, Chen S et al. KAEMPFEROL, A FLAVONOID COMPOUND FROM GYNURA MEDICA INDUCED APOPTOSIS AND GROWTH INHIBITION IN MCF-7 BREAST CANCER CELL. African Journal of Traditional, Complementary and Alternative Medicines. 2016;13(4):210–215.

Fagundes R, Teixeira LK. Cyclin E/CDK2: DNA Replication, Replication Stress and Genomic Instability. Front Cell Dev Biol. 2021;9:774845.

Pellarin I, Dall’Acqua A, Favero A, Segatto I, Rossi V, Crestan N et al. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduct Target Ther. 2025;10(1):11.

Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S et al. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 2019;37(14):1169–1178.

Anbalagan M, Rowan BG. Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer. Mol Cell Endocrinol. 2015;418:264–272.

Suhail M, AlZahrani WM, Shakil S, Tarique M, Tabrez S, Zughaibi TA et al. Analysis of some flavonoids for inhibitory mechanism against cancer target phosphatidylinositol 3-kinase (PI3K) using computational tool. Front Pharmacol. 2023;14:1236173.

Zheng Z-Z, Chen L, Hu G-S, Peng B-L, Huang Q-X, Wang A et al. Nuclear receptor ESRRA promotes ERα-positive breast cancer through dual action on super enhancers and promoters to regulate gene transcriptional programs. Sci Bull (Beijing). 2025;70(22):3822–3839.

Peng R, Liu X, Chen C-C, Guo R-T, Min J. Development of PROTACs targeting estrogen receptor: an emerging technique for combating endocrine resistance. RSC Med Chem. 2025;16:1023–1036.




DOI: https://doi.org/10.24198/ijbp.v6i1.69730

DOI (PDF): https://doi.org/10.24198/ijbp.v6i1.69730.g28017

Refbacks

  • Saat ini tidak ada refbacks.


##submission.license.cc.by-nc4.footer##

IJBP by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License